Molly Czachor

Ms. Molly Czachor

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Bioactive Materials
Verified
Journal Article
Open access
ANAnna Laura Nelson
Anna Laura Nelson
CMChiara Mancino
Chiara Mancino
XGXueqin Gao
Xueqin Gao
JCJoshua A. Choe
Joshua A. Choe
LCLaura Chubb
Laura Chubb
NENicole Ehrhart
Nicole Ehrhart
Fractures continue to be a global economic burden as there are currently no osteoanabolic drugs approved to accelerate fracture healing. In this study, we aimed to develop an osteoanabolic therapy which activates the Wnt/β-catenin pathway, a molecular driver of endochondral ossification. We hypothesize that using an mRNA-based therapeutic encoding β-catenin could promote cartilage to bone transformation formation by activating the canonical Wnt signaling pathway in chondrocytes. To optimize a delivery platform built on recent advancements in liposomal technologies, two FDA-approved ionizable phospholipids, DLin-MC3-DMA (MC3) and SM-102, were used to fabricate unique ionizable lipid nanoparticle (LNP) formulations and then tested for transfection efficacy both in vitro and in a murine tibia fracture model. Using firefly luciferase mRNA as a reporter gene to track and quantify transfection, SM-102 LNPs showed enhanced transfection efficacy in vitro and prolonged transfection, minimal fracture interference and no localized inflammatory response in vivo over MC3 LNPs. The generated β-cateninGOF mRNA encapsulated in SM-102 LNPs (SM-102-β-cateninGOF mRNA) showed bioactivity in vitro through upregulation of downstream canonical Wnt genes, axin2 and runx2. When testing SM-102-β-cateninGOF mRNA therapeutic in a murine tibia fracture model, histomorphometric analysis showed increased bone and decreased cartilage composition with the 45 μg concentration at 2 weeks post-fracture. μCT testing confirmed that SM-102-β-cateninGOF mRNA promoted bone formation in vivo, revealing significantly more bone volume over total volume in the 45 μg group. Thus, we generated a novel mRNA-based therapeutic encoding a β-catenin mRNA and optimized an SM-102-based LNP to maximize transfection efficacy with a localized delivery.

29 August 2025 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
ZWZachary M. Working
Zachary M. Working
MCMolly Czachor
Molly Czachor
ANAnna Laura Nelson
Anna Laura Nelson
KOKelsey M. O’hAra
Kelsey M. O’hAra
KLKaralynn Lancaster
Karalynn Lancaster
OIOn behalf of the Vita-Shock Investigators
On behalf of the Vita-Shock Investigators
Background: Clinical determination of bone fracture healing remains qualitative, typically determined through the combination of plain film radiographs, clinical assessment, and patient-reported pain. Importantly, standard radiographs can only detect bone formation in the fracture site after sufficient tissue mineralization has occurred, restricting utility to the later stages of bone repair. A more rigorous method for determining fracture healing progression could significantly improve patient care. Quantitative biomarkers have gained diagnostic value in many clinical indications. Multiple bone turnover biomarkers have been successfully utilized for diagnosis and clinical management of osteoporosis. However, there remains limited evidence for the correlation and diagnostic efficacy of these biomarkers when applied to fracture repair. Methods and findings: Here we present data from a large cohort of participants without (n = 111) or with (n = 153) fracture with the primary outcome of interest our blood-based biomarker which detects the degradation product of the trimeric collagen X protein (CXM). Collagen X is a transient extracellular matrix protein synthesized by hypertrophic chondrocytes during the soft callus phase of endochondral fracture repair. Our data show that healthy patients with an age range of 21−85 years without fracture (enrolled 2018−2020) have low circulating levels of CXM (median = 563.4 pg/mL; interquartile range (IQR) [483.2, 771.1]) that do not vary independently with age (r = 0.04, p = 0.26) or sex (p = 0.42). Fracture data includes patients with an acute closed or low grade open (Gustilo type I or II) tibial or femoral shaft fracture from a secondary analysis of the VitaShock study (NCT02786498, n = 102: enrolled through the University of Maryland 2016−2019), complemented by a new prospectively enrolled observational study that recruited from the Oregon Health & Science University level 1 academic trauma center (n = 51: enrolled 2019−2023) that were followed until the patient was deemed clinically healed or until they failed to return for follow-up. We show that in serum CXM positively correlates to the bone biomarkers N-terminal propeptide of type I procollagen (P1NP, r = 0.50, p < 0.0001), C-terminal telopeptide of type I collagen (CTX, r = 0.40, p < 0.0001), and osteocalcin (r = 0.26, p = 0.0411); with a negative correlation to the obesity biomarker leptin (r = −0.31, p = 0.0138). Further, patients with early healing exhibited a peak in CXM at 6 weeks of 1,092 pg/mL (95% confidence interval (CI) [804.8, 1,379]), which was significantly higher than patients with normal healing of 630.8 pg/mL (95% CI [399.9, 861.8]; p = 0.016). We then show that we can reliably transfer this assay from serum collection through venipuncture to a dried blood spot (DBS) collected by finger prick (r = 0.75, Serum = 0.4217*DBS + 181.9, p < 0.0001). Using DBS, the prospective clinical observational study finally suggests that median time-to-peak CXM is at 25.5 days following the elimination of outliers (n = 6) using Robust Regression and Outlier Removal (ROUT, Q = 1%). This study did not find significant differences in CXM expression according to age, sex, or bone that are likely due to the main limitation of an observational study. Conclusion: This rigorous data set supports the future prospective use of the CXM biomarker collected by finger prick in interventional fracture studies and/or in observational studies requiring quantitative assessments of long-bone healing.

9 October 2026 in Aging Cell
Verified
Journal Article
Open access
PDF file
CLChristian Lewis
Christian Lewis
HLHunter Levis
Hunter Levis
JHJonah Holbrook
Jonah Holbrook
JPJacob T. Polaski
Jacob T. Polaski
TJTimothy D. Jacobsen
Timothy D. Jacobsen
RBRobby D. Bowles
Robby D. Bowles
Senescence has been shown to contribute to the progression of aging‐related diseases including degenerative disc disease (DDD). However, the mechanisms regulating senescence in the intervertebral disc (IVD) and other tissues/diseases remain poorly understood. Recently, ZNF865 (BLST) was identified as a previously uncharacterized zinc finger protein that regulates a wide array of genes related to protein processing, cell senescence, and DNA damage repair. Here, we show that ZNF865 expression decreases with age and pathology in human and mouse IVD samples. Utilizing CRISPR‐guided gene modulation, we show that ZNF865 is necessary for healthy cell function and is a critical protein in regulating senescence and DNA damage in IVD cells, with implications for a wide range of tissues and organs. We also demonstrate that downregulation of ZNF865 induces senescence in asymptomatic human nucleus pulposus (NP) cells. Conversely, restoration in degenerative NP cells mitigates senescence, SASP expression, and DNA damage, enhances ECM anabolism, and restores chromatin accessibility and gene expression to a healthy state. In vivo, CRISPRi of ZNF865 induces disc degeneration and painful behaviors. Collectively, our findings establish ZNF865 as a novel regulator of genome stability and a potential therapeutic target for mediating senescence/DNA damage in aging related diseases.

22 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
XGXueqin Gao
Xueqin Gao
JRJoanna Roder
Joanna Roder
LMLucas Minas
Lucas Minas
JSJacob B Singer
Jacob B Singer
CBChloe Barton
Chloe Barton
JHJohnny Huard
Johnny Huard
Fisetin is a natural flavonoid that possesses antioxidant, anti-inflammatory, anti-senescence, and neuroprotective effects in preclinical studies. This double-blind randomized clinical trial investigated the effects of two fisetin dosing regimens on senescent gene expression in peripheral blood mononuclear cells (PBMCs) in elderly humans (> 55 years old). Participants were randomized to Daily dose (100mg/day, N = 41) or Bolus dose (20mg/kg for two consecutive days on and 28 days off, N = 40) for 60 days. Blood draw, PBMC isolation, RNA extraction and quantitative polymerase chain reaction (Q-PCR) for 5 target genes were performed at baseline, and days 15, 35, 45 and 60. At the primary endpoint, day 45, both fisetin dosing regimens significantly decreased galactosidase beta 1 (GLB1) and P16 INK4A (P16) gene expression. Bolus dose also significantly reduced macrophage migration inhibition factor (MIF) and alpha-L-fucosidase 1 (FUCA1) compared to baseline and decreased MIF compared to daily dose. Further, Bolus dose significantly decreased GLB1 and MIF at days 15, 35, 60, and P16 at days 15, 35 as well as FUCA1 at day 35 compared to baseline. Hence, Bolus dosing of fisetin is more effective than Daily dosing for reducing cellular senescent genes in PBMCs isolated from elderly human blood.